agents in a microplate. The mixture was pre-incubated for 10 min, after which 25 ml of AChE (0.226 U/ml) was added and the reaction was then scanned at 405 nm for 10 min using a microplate reader, Model Biotek uQuant MQX200 (Winooski, VT, U.S.A.).
Animals All the experiments were performed using male Institute of Cancer Research (ICR) mice weighing 28-30 g and purchased from the Orient Co., Ltd., a branch of Charles River Laboratories (Seoul, Korea), according to the guidelines of the Principle of Laboratory Animal Care (NIH publication No. 85-23, revised 1985) . The mice were housed 5 or 6 per cage, allowed access to water and food ad libitum, and maintained at an ambient temperature of 22Ϯ1°C with 50Ϯ10% humidity and a 12 h diurnal light cycle (lights on 07:30-19:30 h), prior to testing. All behavioral experiments were carried out in a room adjacent to the housing room under the same ambient conditions.
Passive Avoidance Test The passive avoidance test was performed in identical illuminated and non-illuminated boxes (Gemini Avoidance System, San Diego, CA, U.S.A.) according to the previous method of Kim et al. 11 ) The illuminated compartment (20ϫ20ϫ20 cm) contained a 100 W bulb, and the floor of the non-illuminated compartment (20ϫ20ϫ 20 cm) was composed of 2 mm stainless steel rods spaced 1 cm apart. These compartments were separated by a guillotine door (5ϫ5 cm). For the acquisition trial, mice were initially placed in the illuminated compartment and the door between the two compartments was opened 10 s later. When the mice entered the dark compartment, the door automatically closed and an electrical foot shock (0.5 mA) of 3 s durations was delivered through the stainless steel rods. One hour before the acquisition trial, mice received mangiferin (10, 20 , 40 mg/kg, per os (p.o.)) or tacrine (10 mg/kg, p.o.) as a positive control. Memory impairment was induced by scopolamine treatment (1 mg/kg, intraperitoneally (i.p.)) 30 min after the administration of test agent, tacrine, or 10% Tween 80 solution. Control animals were administered 10% Tween 80 solution alone. Twenty-four hours after the acquisition trial, the mice were again placed in the illuminated compartment for the retention trials. The time taken for a mouse to enter the dark compartment after opening the door was measured as latency times in both acquisition and retention trials, with a maximum of 180 s.
Morris Water Maze Test The Morris water maze is a circular pool (90 cm in diameter and 45 cm in height) with a featureless inner surface. The pool was filled to a depth of 30 cm with water containing 500 ml of milk (20Ϯ1°C) according to the method of Kim et al. 11) The tank was placed in a dimly lit, soundproof test room with various visual cues. The pool was conceptually divided into quadrants, and a white platform (6 cm in diameter and 29 cm high) was then placed in one of the pool quadrants and submerged 1 cm below the water surface so that it was not visible at water level. The first experimental day was dedicated to swimming training for 60 s in the absence of the platform. During the four subsequent days, the mice were given four trials per day with the platform in place. When a mouse located the platform, it was permitted to remain on it for 10 s. If the mouse did not locate the platform within 60 s, it was placed on the platform for 10 s. The animal was taken to its home cage and was allowed to dry under an infrared lamp after each trial. The time interval between each trial was 30 s. During each trial, the time taken to find the hidden platform (latency) was recorded using a video camera-based Ethovision System (Nodulus, Wageningen, The Netherlands). For each training trial, mice were placed in the water facing the pool wall in different pool quadrants, with a variable order each day. One day after the last training trial sessions, mice were subjected to a probe trial session in which the platform was removed from the pool and mice allowed to swim for 60 s to search for it. A record was kept of the swimming time in the pool quadrant where the platform had previously been placed. Mangiferin (20 mg/kg, p.o) or tacrine (10 mg/kg, p.o.) as a positive control was given 1 h before the first trial session every consecutive day. Memory impairment was induced in mice with scopolamine (1 mg/kg, i.p.) at 30 min after treatment with mangiferin. The control group received 10% Tween 80 solution only.
Enzyme-Linked Immunosorbent Assay (ELISA) in Brain Hippocampus For the ELISA of TNF-a, the hippocampus was removed from the brains of scopolaminetreated mice with or without test agents and homogenized in 1 ml ice-cold lysis buffer (radio-immunoprecipitation assay, RIPA) containing 1% protease inhibitor cocktail and 1% phosphatase inhibitor cocktail according to the method described by Lee et al. 12) The lysate was centrifuged (15000ϫg, 4°C) for 15 min, and the supernatant transferred to 96-well ELISA plates. TNF-a concentration was determined using commercial ELISA kits (Pierce Biotechnology, Inc., Rockford, IL, U.S.A.).
Acetylcholine Assay in Brain Hippocampus
To assay acetylcholine levels, the hippocampipus was removed from the brains of mice and stored at Ϫ70°C until analysis. The brain samples were thawed unassisted at room temperature and homogenized and deproteinized using 100% methanol. After centrifuging at 20000ϫg for 10 min, the homogenate supernatant was injected onto an LC-MS/MS (a Waters 2795 alliance system, Waters, Milford, MA, U.S.A.) equipped with an automatic sample injector): a column, Shiseido capcell pak UG 120 CN (50ϫ2.0 mm i.d., S-5 mm); mobile phase, 10 mM ammonium formate pH 3.09 (pH adjusted with formic acid) in 100% methanol; flow rate, 0.2 ml/min. The column was maintained at a temperature of 40°C during HPLC analysis and the injection volume was set to 10 ml. MS experiments were performed using a Micromass Quattro API. The mass spectrometer was operated in electrospray positive ionization mode (cone voltage: 19V). Multiple reaction monitoring (MRM) data acquisition for the transitions mass: Ach (m/z 146→87) was achieved with a collision energy of 15 eV, and a dwell time of 0.50 s. Nitrogen (set at approximately 550 l/h) was used for the nebulising and desolvation gases, and the desolvation temperature was set at 350°C.
Assay of NF-k kB Activation in TNF-a a-Stimulated BV-2 Cells The immortalized murine BV-2 cells that exhibit both the phenotypic and functional properties of reactive neuronal 13) were cultured in the Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum and 1% antibiotics. The cultures were maintained at 37°C in humidified 5% CO 2 and split once every 2 d. In all the experiments, BV-2 cells were treated with or without mangiferin (50 or 100 mM) or tacrine (5 mM) 60 min before the addition of TNF-a in serum-free DMEM. Mangiferin and tacrine were dissolved in DMSO and the final concentration of DMSO added to cells never exceeded 0.1%.
Immunoblot analyses of NF-kB (p65 and phospho-p65) and b-actin were performed according to the method described by Bae et al. 12, 14) BV-2 cells (1.5ϫ10 6 cells on 60 mm dish) were incubated for a day. The cells were pretreated with test agents for 60 min. Then, the cells were stimulated with scopolamine or TNF-a for 30 min and washed in 2-3 ml of ice-cold phosphate buffered saline (PBS), centrifuged at 1000ϫg for 5 min. This was followed by resuspension of the pelleted cells in 1 ml of RIPA lysis buffer containing 1% protease inhibitor cocktail and 1% phosphatase inhibitor cocktail. After centrifugation, the supernatant was subjected to electrophoresis on a 10% sodium dodecyl sulfate-polyacrylamide gel, and then transferred to a nitrocellulose membrane. Immunodetection for pp65 and p65 was performed using an enhanced chemiluminescence detection kit.
Statistics Values are expressed as meansϮS.E.M. For the passive avoidance and Morris water maze test, data were analyzed by a Kruskal-Wallis non-parametric ANOVA test. If the results were significant, each treatment group was compared using the Tukey's post hoc test. Statistical significance was set at pϽ0.05. For the microplate assay, data were analyzed by a one-way analysis of variance (ANOVA) test. If the results were significant, each group was compared using the Dunnett's post hoc test. Statistical significance was set at pϽ0.05.
RESUTLS

Mangiferin Inhibits AChE
We performed a bio-guided fractionation strategy using a microplate assay for AChE inhibition to identify active AA isolates. The n-BuOH fraction showed greater inhibition than the CHCl 3 and H 2 O fractions. The n-BuOH fraction was further subjected to silica gel column chromatography to yield six subfractions, with subfraction FB5 being the most potent. Five compounds were isolated from FB5, with mangiferin being identified by comparison of spectral data (MS, 1 H-and 13 C-NMR) with references. Mangiferin inhibited AChE activity in a dose-dependent manner, with an IC 50 value of 62.8 mM (Fig. 2) .
Mangiferin Ameliorates Memory Impairment Induced by Scopolamine We then tested the effect of mangiferin on scopolamine-induced deficits in the passive avoidance test, which is largely dependent on long-term memory. The stepthrough latency of scopolamine treated mice was significantly shorter than that of vehicle-treated control mice (Fig.  3, pϽ0.05) . Mangiferin increased this scopolamine-induced reduction in step-through latency by 44% (10 mg/kg), 65% (20 mg/kg), and 59% (40 mg/kg). During the acquisition trial, no differences in latencies were observed among the groups. Tacrine (10 mg/kg), as a positive control, restored the step-through latency to 68% of the control group, consistent with previously published data. 15) In the Morris water maze test, scopolamine treatment produced longer escape latencies in the training trials than the control group (Fig. 4) . Mangiferin (20 mg/kg) significantly shortened this latent escape time, as did tacrine. Treatment with mangiferin and tacrine also significantly ameliorated the decreased swimming time in the platform quadrant induced by scopolamine during the probe trial.
Mangiferin Increases Acetylcholine Level Reduced by Scopolamine in Mice Brain
To understand the mechanism by which mangiferin ameliorated scopolamine-induced memory deficits in mice, we measured the levels of acetylcholine in the hippocampus of the mouse brain (Fig. 5 ). The treatment with scopolamine significantly reduced acetylcholine levels (pϽ0.05). However, treatment with mangiferin at a dose of 20 mg/kg recovered the reduced acetylcholine level by 74.9% (pϽ0.05). This effect was comparable to that of tacrine.
Mangiferin Inhibits NF-k kB Activation in Scopolamine or TNF-a a-Stimulated BV-2 Cells To investigate whether scopolamine, frequently used to prepare memory deficit animal models, could induce proinflammatory cytokines, scopolamine was intraperitoneally injected into mice and the levels of TNF-a in their brain hippocampus was measured. The TNF-a level was significantly increased 1.7-fold, respec- (Fig. 6) . However, when mangiferin at doses of 10 and 20 mg/kg was orally administered into scopolamine-stimulated mice, it potently inhibited the effect of scopolamine by 32% and 82%, respectively. Its inhibitory potency was comparable to that of tacrine.
We further investigated whether TNF-a or scopolamine could activate transcription factor NF-kB in BV-2 microglial cells (Fig. 7) . Scopolamine and TNF-a activated NF-kB in BV-2 cells. Of them, TNF-a more potently activated NF-kB. tive function with age. 16) Scopolamine, an anti-cholinergic agent, reduces synaptic acetylcholine activity without changing acetylcholine concentration, and also influences delta, theta, alpha and beta activity in electroencephalography (EEG), which partially mimics EEG changes in patients with senile dementia or dementia of the Alzheimer type. 17) Thus, scopolamine treatment represents a good model for the learning and memory changes that occur during CNS aging.
Previous studies suggested that AA might attenuate learning deficits due to brain damage and ageing in rodents. 9, 18, 19) Of its constituents, sarsasponin and timosaponin BII enhanced learning and memory in rats with amyloid b-peptide (25-35)-induced dementia. 19) Sarsasapogenin also improved learning and memory in scopolamine-treated mice, but did not inhibit AChE or occupy muscarinic acetylcholine receptor binding sites. 9) In the preliminary experiment, we found that AA inhibited AChE. We then isolated mangiferin, the main constituent (Ͼ2%) of AA, which was found to be an inhibitor of AChE. We thus tested the ability of mangiferin to improve learning and memory deficits in scopolamine-treated memory-deficient mice. Mangiferin improved the step-through latency reduced by scopolamine treatment, with no differences in latency during the acquisition trial, indicating a lack of effect on the general behavior in mice. When the Morris water maze test was used to assess hippocampal-dependent spatial learning and long-term memory, 20) mangiferin shortened scopolamine-induced increases in escape latency time and showed similar improvements in the quadrant platform. Thus, mangiferin improved long-term memory in scopolamine-induced amnestic mouse models by inhibiting AChE, like AChE inhibitors previously reported. 3, 11) Mangiferin may reverse deficits in hippocampal long-term memory via cholinergic enhancement.
To elucidate the mechanism by which mangiferin ameliorated cholinergic memory deficits, we analyzed the acetylcholine levels in the hippocampus of scopolamine-treated mice. Interestingly, the levels of acetylcholine were significantly reduced in scopolamine-treated mice. However, treatment with mangiferin in scopolamine-treated mice significantly increased the reduced acetylcholine level. Its effects were comparable to that of tacrine, although the inhibitory effect of mangiferin against AChE was weaker than that of tacrine. These results may be due to differences between the absorption of these compounds into the blood or brain, or other factors, such as cholinergic receptor stimulation. In addition, the levels of proinflammatory cytokines, TNF-a but not interleukin (IL)-6 were significantly increased in the hippocampus of scopolamine-treated mice. Thus, scopolamine may reduce the production of acetylcholine and TNF-a in the brain. However, mangiferin treatment in scopolaminetreated mice significantly inhibited the increase of TNF-a. Scopolamine and TNF-a also caused the activation of NFkB, which is a representative transcription factor for proinflammatory cytokines, in BV-2 microglial cells. Mangiferin inhibited NF-kB activation in BV-2 cells stimulated by scopolamine or TNF-a. The result was supported by previous studies showing that mangiferin exhibits anti-inflammatory effects, scavenges free radicals, and reduces oxidative stress. [21] [22] [23] [24] Mangiferin also rescues neurons from cell death in acute injury and reduces neurological deficits caused by ischemic damage to the brain. 25) These findings suggest that scopolamine may cause cholinergic neuron injury and inflammation in the brain and that mangiferin may improve memory deficits by acetylcholine esterase inhibition or cholinergic receptor stimulation and inhibition of NF-kB activation. Finally we suggest that AA and its main constituent, mangiferin, can improve long-term cholinergic memory deficits.
